1237261-60-7

Basic information

• Product Name: (1S,2R)-2-(chloromethyl)-N,N-diethyl-1- phenylcyclopropanecarboxamide
• Synonyms: (1S,2R)-2-(chloromethyl)-N,N-diethyl-1- phenylcyclopropanecarboxamide
• CAS NO: 1237261-60-7
• Molecular Weight: 265.783
• Mol File: 1237261-60-7.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: (1S,2R)-2-(chloromethyl)-N,N-diethyl-1- phenylcyclopropanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,2R)-2-(chloromethyl)-N,N-diethyl-1- phenylcyclopropanecarboxamide(1237261-60-7)
• EPA Substance Registry System: (1S,2R)-2-(chloromethyl)-N,N-diethyl-1- phenylcyclopropanecarboxamide(1237261-60-7)

Safety Data

• Hazardous Substances Data: 1237261-60-7(Hazardous Substances Data)

Usage

General Description

The chemical compound (1S,2R)-2-(chloromethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide is a complex organic molecule with a cyclopropane ring and a chloromethyl functional group. It also contains a diethylamine group and a phenyl group. (1S,2R)-2-(chloromethyl)-N,N-diethyl-1- phenylcyclopropanecarboxamide is commonly used as a building block in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. It has potential therapeutic applications due to its diverse structural features, such as its ability to interact with various biological targets. The presence of the chloromethyl group makes it a versatile precursor for further chemical modifications, allowing for the potential development of new drug candidates. Additionally, its cyclopropane ring structure contributes to its overall stability and reactivity in various chemical reactions.

Upstream product

• 172015-99-5 (1 S,2 R)-N,N-diethyl-2-(hydroxymethyl)-1-phenylcyclopropane-carboxamide 
• 109-89-7 diethylamine 
• 140-29-4 phenylacetonitrile 
• 63106-93-4 (1S,5R)-1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one 

Downstream Products

• 1237261-65-2 (1S,2R)-2-((1,3-dioxoisoindolin-2-yl)methyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide-cyclopropanecarboxamide 
• 96847-54-0 (1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide 
• 101152-94-7 (1S,2R)-milnacipran hydrochloride 
• 174848-98-7 (1S,2R)-2-(azidomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide 

Relevant articles and documents

Preparation method of milnacipra hydrochloride intermediate

The invention provides a preparation method of an intermediate hydrochloride intermediate. Belong to chemical medicine preparation technical field. To the preparation method, the compound having the structure of the formula (II) is added into the methanol

Preparation method of levomilnacipran hydrochloride

The invention relates to the field of chemical medicines and organic synthesis and in particular relates to a preparation method of levomilnacipran hydrochloride. Aiming at solving the problems of anexisting method for preparing the levomilnacipran hydrochloride that the cost is relatively high or a generation process is relatively dangerous so that large-scale industrial production is limited, the preparation method is characterized by comprising the following steps: [1] enabling phenylacetonitrile and (R)-2-chloromethyl ethylene oxide to react under the action of sodium amide to obtain a compound 1; then carrying out hydrolysis cyclization on the compound 1 to obtain a compound 2; [2] enabling the compound 2 and thionyl chloride to react in alcohol, so as to obtain a compound 3; [3] enabling the compound 3 to be subjected to exchange reaction through introducing nitryl and amino, so as to obtain a compound 6; [4] reducing nitryl in the compound 6 and forming salt in situ to obtain the levomilnacipran hydrochloride. The preparation method provided by the invention is applicable to industrial production of the levomilnacipran hydrochloride.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.